Canaccord Genuity Initiates Coverage on Medicine Mind (OTCMKTS:MMEDF)

Investment analysts at Canaccord Genuity initiated coverage on shares of Medicine Mind (OTCMKTS:MMEDF) in a report released on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.

Shares of MMEDF opened at $0.34 on Tuesday. Medicine Mind has a 12-month low of $0.08 and a 12-month high of $1.00. The firm has a 50-day moving average price of $0.35.

About Medicine Mind

Mind Medicine, Inc, a neuro-pharmaceutical company, discovers, develops, and deploys psychedelic inspired medicines to improve health and wellness, and alleviate suffering. The company focuses on the development of 18-methoxycoronaridine, an alpha-3-beta-4 nicotinic receptor antagonist that modulates excessive dopamine fluctuations in the mesolimbic system of the brain for treating various forms of addiction.

Further Reading: What is the Ex-Dividend Date in Investing?

The Fly

Receive News & Ratings for Medicine Mind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicine Mind and related companies with's FREE daily email newsletter.